CYP2C9 and multiple sclerosis: Specifically, testing is required for the sphingosine-1-phosphate receptor modulator siponimod in multiple sclerosis, and CYP2C9 genotype is also considered actionable information for dosage of warfarin, phenytoin, and several non-steroidal anti-inflammatory drugs (NSAIDs) [35].